- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03608176
Evaluation of the Plant-based Approaches to Stop Obesity Diet for the Treatment of Overweight and Obesity (PASO diet)
April 14, 2020 updated by: Rolando Giovanni Díaz Zavala, Universidad de Sonora
Evaluation of the Efficacy of Plant-based Approaches to Stop Obesity Diet in Comparison With a Control Group on Body Weight in Mexican Adults With Overweight and Obesity: Randomized Controlled Trial
The accumulation of excess of body weight is one of the most important problems worldwide, thus effective and accessible treatments are required.
Some authors highlighted that treatment is focused solely on lifestyle (diet, physical activity, behavioral therapy) has a limited effect on body weight because it does not consider the biological mechanisms linked to weight loss in patients with obesity.
On the other hand, drugs and bariatric surgery consider these biological approaches; however, its costs, safety and effectiveness limits its use on a large scale.
Research studies support the existence of compounds in plants (such as epigallocatechin gallate, caffeine, cinnamaldehyde, fiber), and water with biological properties that would contribute to the treatment of overweight and obesity.
However, at the moment, these compounds have only been evaluated individually and their effects have been significant but limited clinically, therefore, more research studies are needed to evaluate whether several of these compounds contained in common plants synergistically have a clinical impact on the management of overweight and obesity.
The present work integrates diverse plant-based approaches to stop obesity and it is compared with a control group and a waiting list group.
The main aim is to evaluate the efficacy of the Plant-based Approaches to Stop Obesity diet (PASO diet) compared with a control group on body weight at 3 months in Mexican adults with overweight and obesity.
This is a pilot study designed as a randomized controlled trial.
The study will be conducted with a (n=36).
The primary outcome is the change in body weight from baseline to 3 months.
Secondary outcomes will be the changes from baseline to 3 months in body mass index, waist circumference, systolic and diastolic blood pressure, symptoms of depression, quality of life scales and biochemical parameters (fasting glucose, total cholesterol, LDL cholesterol, HDL-cholesterol, triglycerides and gamma glutamyl transferase).
Additionally two 24-hour dietary recall will be measured at baseline and 3 months to evaluate adherence to the intervention.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
36
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Sonora
-
Hermosillo, Sonora, Mexico, 83000
- Recruiting
- Centro de Promoción de Salud Nutricional (CPSN)
-
Contact:
- Rolando Giovanni Díaz Zavala, Ph.D.
- Phone Number: 4632 6622893793
- Email: giovanni.diaz@unison.mx
-
Principal Investigator:
- Rolando Giovanni Díaz Zavala, Ph.D.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Mexican adults (> 20 years and <55)
- Residents of the city of Hermosillo, Sonora
- Obesity (BMI> 25 and <45)
- Availability of time to participate in the study.
- Economic capacity to acquire the assigned diet
- Grant informed consent
- Keep a dietary record for one week prior to the intervention
Exclusion Criteria:
- Medical conditions that constitute a contraindication for the intervention, such as de-controlled diabetes, dyslipidemia with pharmacological treatment, blood pressure ≥160 / 100 mmHg, heart failure, renal failure, etc.
- Previous bariatric surgery
- Participate in another intervention or treatment for the management of obesity
- Use of drugs or substances with an effect on weight, for example, metformin, orlistat or corticoids
- Weight loss> 5% of total body weight in the last 4 months
- Pregnancy or lactation
- Another member of the family or acquaintance who has agreed to participate in the study
- Consumption of more than 10 alcoholic drinks per week
- Use of addictive substances as drugs of abuse
- Psychiatric condition that prevents adherence to treatment, such as severe depression, bipolarity and schizophrenia Illiteracy
- Gastrointestinal problems or any condition where coffee, tea or cinnamon are not well tolerated or contraindicated
- People who drink more than 4 cups of coffee (tea) per day or its equivalent in caffeinated beverages.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PASO diet group
|
This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
They will also be instructed to consume green tea (2 cups/day for 3 days/week), black tea (2 cups/day for 2 days/week), coffee (2 cups/day for 2 days/week), cinnamon (1 tsp/day for at least 3 days/week), psyllium fiber (3 tsp/day/week) and water (1.5 L/day/week).
|
Active Comparator: Low-fat diet group
|
This group include a low-fat, low calorie diet (1200-1800 kcal), in addition of a behavioral change protocol.
|
Other: Waiting list group
|
This group will only receive written information with recommendations on healthy eating.
When the study finished, this group will receive a behavioral change protocol with a low-fat, low calorie diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in body weight
Time Frame: baseline to 3 months
|
baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in fasting glucose
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in total cholesterol
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in LDL-cholesterol
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in HDL-cholesterol
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in triglycerides
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in gamma glutamyl transferase
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in waist circumference
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in body fat percentage
Time Frame: baseline to 3 months
|
baseline to 3 months
|
|
Change in the Beck Depression Inventory score
Time Frame: baseline to 3 months
|
The Beck Depression Inventory (BDI) is a 21-item questionnaire that assesses mood over the previous week.
Total scores range from 0 to 63, with higher values indicating greater symptoms of depression.
Scores of 0-9 reflect minimal (subclinical) symptoms, values of 10-18, 19-29, and ≥30 indicate mild, moderate, and severe symptoms of depression, respectively.
|
baseline to 3 months
|
Change in the Short Form-36 Health Survey score
Time Frame: baseline to 3 months
|
The SF-36 Health Survey evaluates aspects of the quality of life in adult populations (over 16 years of age).
The result of its application is the generation of eight concepts or scales of health, result of the average of the sum of the questions contained in the questionnaire for each concept.
These concepts are: physical function, physical role, corporal pain, general health, vitality, social function, emotional role and mental health.
The SF-36 is a self-applied instrument and contains 36 questions.
For each scale, the answers to each question are coded and recoded (10 questions), and the results are interpreted on a scale of 0 to 100, lower results indicate poorer health and greater result better health).
|
baseline to 3 months
|
Change in systolic and diastolic blood pressure
Time Frame: baseline to 3 months
|
baseline to 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Rolando G Díaz Zavala, Ph.D., Universidad de Sonora
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 10, 2018
Primary Completion (Anticipated)
July 31, 2021
Study Completion (Anticipated)
July 31, 2021
Study Registration Dates
First Submitted
July 23, 2018
First Submitted That Met QC Criteria
July 23, 2018
First Posted (Actual)
July 31, 2018
Study Record Updates
Last Update Posted (Actual)
April 15, 2020
Last Update Submitted That Met QC Criteria
April 14, 2020
Last Verified
April 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PASOdiet-OBMEX-2018
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overweight and Obesity
-
University Hospital, LilleNational Research Agency, France; European Union; University of Lille Nord de... and other collaboratorsNot yet recruitingOverweight and Obesity | Overweight, Childhood | Overweight, Infant
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
Institut Investigacio Sanitaria Pere VirgiliCompletedObesity, Childhood | Overweight and Obesity | Overweight, ChildhoodSpain
-
Memorial Sloan Kettering Cancer CenterRecruitingObesity | Overweight | Overweight and Obesity | Obese | Overweight or ObesityUnited States
-
Holbaek SygehusUniversity of Copenhagen; University of Florida; University of Minnesota; Hebrew... and other collaboratorsRecruitingChildhood Overweight and ObesityDenmark
-
Universidade do Extremo Sul Catarinense - Unidade...RecruitingObesity | Overweight and Obesity | Obesity; Endocrine | Overweight, Obesity and Other HyperalimentationBrazil
-
Mexican National Institute of Public HealthUNICEFCompleted
-
Universidade do PortoFundação para a Ciência e a Tecnologia; Administração Regional de Saúde do... and other collaboratorsCompletedOverweight and ObesityPortugal
-
University of British ColumbiaTerminatedOverweight and ObesityCanada
-
National Taiwan University HospitalCompleted
Clinical Trials on PASO diet group
-
Universitätsklinikum KölnBiosense Webster, Inc.UnknownHeart Failure | Cardiomyopathies | Ventricular Tachycardia | PVC - Premature Ventricular ComplexGermany
-
Daewoong Pharmaceutical Co. LTD.CompletedIdiopathic Pulmonary FibrosisKorea, Republic of
-
University Hospital TuebingenRecruiting
-
University of CreteCompletedObstructive Sleep Apnoea | Hypopnoea SyndromeGreece
-
Instituto Tecnológico y de Estudios Superiores...University of Guadalajara; Instituto Tecnológico de TepicCompletedDyslipidemias | Overweight and ObesityMexico
-
Centro di Riferimento per l'Epidemiologia e la...Azienda Sanitaria Locale Torino 1CompletedBreast Cancer | Colorectal Cancer | Lifestyle Risk Reduction | Weight Changes, BodyItaly
-
Children's Hospital of Fudan UniversityRecruiting
-
Rio de Janeiro State UniversityRio de Janeiro State Research Supporting Foundation (FAPERJ)Completed
-
Emory UniversityCompleted
-
Hospital de Clinicas de Porto AlegreCoordenação de Aperfeiçoamento de Pessoal de Nível Superior.; Conselho Nacional...CompletedObesity | Female InfertilityBrazil